Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ANAB
ANAPTYSBIO, INC.
NASDAQ
$56.28
▼ DOWN 1.76% (-1.01)

KEY STATISTICS

Market Cap$1.67 B
52w High$72.36
52w Low$11.40
Dividend Yield—
Frequency—
P/E-52.11
Volume358.57K
Shares Out.29.61M

COMPANY

LEADERSHIP

Daniel R. Faga
CHIEF EXECUTIVE
Daniel R. Faga

COMPENSATION 2026

Salary$706,011
Stock Awards$1,592,001
Incentive Plan Pay$465,968
All Other Comp.$24,310
Total$6,133,943

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 26, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
104

PRICE TARGET

Target High$90.00
Target Low$50.00
Target Median$75.00
Target Consensus$73.14

UPCOMING EARNINGS

DateAug 31, 2026
DayMonday
Rev. Est.$6.67M
AUG
31
MON

SPLIT RECORD

DATETYPERATIO
2026-04-20Forward3:2

PRICE

$56.28 ▼ DOWN 1.76% (−$1.01)
OVERLAYS
$55.50$56.00$56.50$57.009:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM56.28

About AnaptysBio, Inc.

https://www.anaptysbio.com ↗

AnaptysBio, Inc. is a clinical-stage biotech developing immuno-inflammatory therapies like IL-36R antibody Imsidolimab, anti-PD-1 agonist Rosnilimab, and anti-BTLA antibody ANB032, through collaborations with GSK, BMS, and others.

INDUSTRY

Biotechnology

A PRODUCT ANAPTYSBIO, INC. IS KNOWN FOR

Rosnilimab
Rosnilimab

Rosnilimab, an investigational antibody targeting PD-1, is in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, forming a key part of AnaptysBio's immunology pipeline.

COMPETITORS

COMPETITOR
COGT COMPARE
CRNX COMPARE
IMVT COMPARE
MIRM COMPARE
PTGX COMPARE

Revenue by Products

IconPRODUCTQ1-2025Q2-2025Q3-2025
Research and Development Segment$27.77M $22.26M ▼$76.32M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
151
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
0.40% · 838.9K
VTI
0.00% · 648.1K
XSU.TO
0.04% · 508.3K
PBE
2.25% · 159.4K
BR
BRES
1.22% · 149.1K
FYC
0.55% · 140.7K
PSC
0.20% · 97.9K
SCHA
0.02% · 97.5K
DFAS
0.02% · 65.0K
USVM
0.16% · 52.0K
FSMD
0.10% · 43.8K
CANC
0.87% · 32.7K
LABU
0.27% · 30.5K
FSML
0.93% · 24.4K
XRSG.L
0.04% · 18.4K
FSCC
0.24% · 14.1K
GSSC
0.06% · 11.9K
RSSL
0.04% · 9.4K
BBC
0.61% · 5.6K
ETLZ.DE
0.13% · 5.2K
AI
AIMS
0.14% · 2.3K
ESSC
0.20% · 1.4K
SGRW
0.21% · 1.1K
BIB
0.06% · 1.0K
ACSG
0.11% · 1.0K
RFLR
0.05% · 803

INSTITUTIONAL OWNERSHIP

SHARES OWNED
82.29%
HOLDERS
301
TOP 12 OF 301 · RANKED BY POSITION SIZE
Ecor1 Capital, LLC
7.9M sh · $531.91M
Point72 Asset Management, L.P.
2.3M sh · $69.37M
Blackrock, Inc.
1.8M sh · $124.47M
Blackrock Inc.
1.8M sh · $44.35M
Morgan Stanley
1.6M sh · $47.65M
Vanguard Group Inc
1.5M sh · $74.85M
Millennium Management LLC
1.5M sh · $46.52M
Tang Capital Management LLC
1.3M sh · $40.84M
Boxer Capital, LLC
1.3M sh · $43.55M
State Street Corp
1.3M sh · $86.82M
Oppenheimerfunds, Inc.
1.1M sh · $78.59M
First Light Asset Management, LLC
990.2K sh · $30.32M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: PRESIDENT, CEO
Faga Daniel
Purchase · 53.3K shares
2026-03-12
★
OFFICER: CHIEF MEDICAL OFFICER
Lizzul Paul F.
Purchase · 16.7K shares
2026-03-12
★
DIRECTOR
Orwin John A
Purchase · 6.0K shares
2026-06-15
★
DIRECTOR
Schmid John P.
Purchase · 6.0K shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OVERWEIGHT 3
OUTPERFORM 2
HOLD 1
11 GRADES IN THE LAST 12 MONTHS
TD Cowen BUY HC Wainwright & Co. BUY UBS BUY Barclays OVERWEIGHT Piper Sandler OVERWEIGHT Leerink Partners OUTPERFORM Wedbush OUTPERFORM Truist Securities HOLD

SECTORS PEERS

PEERPRICE
DNTH$105.84COMPARE
NRIX$26.21COMPARE
KOD$37.72COMPARE
URGN$43.62COMPARE
XNCR$26.06COMPARE
TSHA$5.77COMPARE
PHAT$9.18COMPARE
BBOT$8.74COMPARE